Thursday, May 15, 2014
Genetics can predict success of psychiatric medications
GeneSight Psychotropic Test
The enhancement of GeneSight Psychotropic test helps clinicians make individualized antidepressant and antipsychotic medication decisions for patients with depression, anxiety, post-traumatic stress disorder bipolar disorder, schizophrenia and other behavioral health disorders. GeneSight Psychotropic now covers 38 FDA-approved medications, including recently approved levomilnacipran (Fetzima®) and vortioxetine (Brintellix®). According to Bryan M. Dechairo, Ph.D., Senior Vice President, Medical Affairs & Clinical Development at Assurex Health, "GeneSight Psychotropic is now the only test to integrate scientifically validated drug response and metabolism genes, including CYP3A4, for a broad range of psychiatric medications into an easy-to-interpret report for clinicians to see which medications may be optimal for individual patients." To learn more about antidepressant and antipsychotic medication see here: http://www.examiner.com/article/genetics-can-predict-success-of-psychiatric-medications.